|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | C07D 405/06 | (2006.01) |
| A61K 45/06 | (2006.01) | ||
| A61K 31/4025 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3133070 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16175117.7 |
| Date of filing the European patent application | 2010-11-24 | |
| (97) | Date of publication of the European application | 2017-02-22 |
| (45) | Date of publication and mention of the grant of the patent | 2019-08-14 |
| (46) | Date of publication of the claims translation | 2019-11-11 |
| (30) | Number | Date | Country code |
| 264748 P | 2009-11-27 | US |
| (72) |
LIU, Hanlan, US
WILLIS, Chris, US
BHARDWAJ, Renu, US
COPELAND, Diane P., US
HARIANAWALA, Abizer, US
SKELL, Jeffrey, US
MARSHALL, John, US
KOCHLING, Jianmei, US
PALACE, Gerard, US
PETERSCHMITT, Judith, US
SIEGEL, Craig, US
CHENG, Seng, US
|
| (73) |
Genzyme Corporation,
50 Binney Street, Cambridge, MA 02142,
US
|
| (74) |
Jelena GERASIMOVIČ,
IĮ "Liudmila Gerasimovič, Patentinis patikėtinis", Vingrių g. 13-42, LT-01141 Vilnius,
LT
|
| (54) | Eligliustatas (GENZ 112638) kaip gliukozilceramido sintazės slopiklis, skirtas naudoti Fabri arba Gošė ligos gydymo būde, kur būdas apima individualios terapinės dozės priderinimą paciento P-450 metabolizmui |
| ELIGLUSTAT (GENZ 112638) AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE FOR USE IN A METHOD OF TREATING FABRY'S OR GAUCHER'S DISEASE, THE METHOD COMPRISING ADJUSTING THE INDIVIDUAL THERAPEUTICAL DOSE TO THE P-450 METABOLISM OF THE PATIENT |
| Payment date | Validity (years) | Amount | |
| 2024-10-24 | 15 | 289.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2025-02-18 |